GlassScriptPhysician profile
William C Dorwart
NPI 1144541335
$2,680.81
in general payments reported to CMS, 2019-2025
32 companies · $788 in 2025
The $788 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $59.77 · 2021: $183 · 2022: $272 · 2023: $499 · 2024: $721 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $338.01 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $220.52 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $195.48 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $176.44 | 2019-2024 | Prolia, Evenity, Repatha |
| Sumitomo Pharma America, INC. | $128.46 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $118.70 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.76 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $109.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.35 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $74.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $57.37 | 2019-2024 | Invega Sustenna |
| Inspire Medical Systems, INC. | $55.04 | 2025 | Inspire |
| Organon LLC | $54.42 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $53.29 | 2025 | |
| Abbott Laboratories | $49.75 | 2022-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $43.46 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $41.79 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Abiomed | $35.97 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.57 | 2023 | Caplyta |
| Almatica Pharma LLC | $27.49 | 2023 | Loreev Xr |
| Glaxosmithkline, LLC. | $25.79 | 2022-2023 | Arexvy, Shingrix |
| Lexicon Pharmaceuticals, INC. | $20.44 | 2023 | Inpefa |
| Ultragenyx Pharmaceutical INC. | $18.61 | 2023 | |
| Ironwood Pharmaceuticals, INC | $16.23 | 2020 | |
| Medtronic, INC. | $14.95 | 2023 | Intellis Adaptivestim |
| Verona Pharma, INC. | $14.22 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $13.98 | 2025 | Veozah |
| Mylan Specialty L.P. | $13.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.28 | 2021 | |
| Eisai INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dorwart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.